Phase 1 Study Will Evaluate The Safety And Tolerability Of Tern-101, An Fxr Agonist In Development For The Treatment Of Nash.Terns Pharmaceuticals Has Announced The Initiation Of Phase 1 Clinical Trial Of Tern-101, A Farnesoid X Receptor (Fxr) Agonist, Being Developed For The Treatment Of Non-Alcoholic Steatohepatitis (Nash). Initiation Of The Study In The Us Follows Us Food And Drug Administration (Fda) Clearance Of The Investigational New Drug Application For Tern-101 Filed Earlier This Year.
